Concurrent use of antioxidants in cancer therapy: an update.

Abstract:

:Some chemotherapeutic agents and all radiation therapy generates reactive oxygen species (ROS), which induce apoptosis in cancer cells. As ROS play a role in drug-induced apoptosis, one might suspect that antioxidants may inhibit ROS and prevent apoptosis of cancer cells. In order to find an answer to whether or not there is any interference between the concurrent use of antioxidants and chemotherapeutic agents, we have reviewed all of the recent available literature. Except for three specific interferences, considerable data exists demonstrating an increased effectiveness, as well as decreased side effects of chemotherapeutic agents when administered with antioxidants.

authors

Akbas HS,Timur M,Ozben T

doi

10.1586/1744666X.2.6.931

subject

Has Abstract

pub_date

2006-11-01 00:00:00

pages

931-9

issue

6

eissn

1744-666X

issn

1744-8409

journal_volume

2

pub_type

杂志文章
  • Acute infusion reactions induced by monoclonal antibody therapy.

    abstract::This article reports recent evidence on epidemiological data concerning monoclonal antibody (mAb) infusion-related anaphylaxis, as well as recent data on the correlation between mAb immunogenicity and safety profiles. Pathogenic mechanisms of mAb-related adverse reactions including hypersensitivity, IgE- and non-IgE-m...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.10.90

    authors: Maggi E,Vultaggio A,Matucci A

    更新日期:2011-01-01 00:00:00

  • 5-Aza-2'-deoxycytidine may enhance the frequency of T regulatory cells from CD4+ naïve T cells isolated from the peripheral blood of patients with chronic HBV infection.

    abstract:OBJECTIVES:Methylation pattern of gene modification is essential for the differentiation of T regulatory cells (Tregs) and 5-Aza-2'-deoxycytidine is a common inhibitor of methylation. This study aimed to investigate the potential effects of Treg polarizing conditions and 5-Aza-2'-deoxycytidine treatment in the differen...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1080/1744666X.2020.1866987

    authors: Fang Y,Yuan XD,Liu HH,Xiang L,Chen LM,Fan YC,Gao S,Wang K

    更新日期:2021-01-13 00:00:00

  • Remission maintenance in ANCA-associated vasculitis: does one size fit all?

    abstract::Introduction: The majority of the patients with anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV) achieve remission with effective induction therapy. Therefore, prevention of relapses and avoiding long-term damage and treatment-related toxicity are major challenges.Areas covered: This review ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2020.1693260

    authors: Berti A,Specks U

    更新日期:2019-12-01 00:00:00

  • Determinants of thyroid autoantibody production in Hashimoto's thyroiditis.

    abstract::Hashimoto's thyroiditis (HT) is the most prevalent thyroid autoimmune disorder, characterized by the presence of specific thyroid autoantibodies (TAb). The development of autoimmunity, including TAb production and clinical presentation of HT, is determined by a complex interplay of genetic susceptibility and several e...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.3.2.217

    authors: Zaletel K

    更新日期:2007-03-01 00:00:00

  • Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature.

    abstract::Adherence to medication in patients with rheumatoid arthritis is low, varying from 30 to 80%. Improving adherence to therapy could therefore dramatically improve the efficacy of drug therapy. Although indicators for suboptimal adherence can be useful to identify nonadherent patients, and could function as targets for ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.12.23

    authors: van den Bemt BJ,Zwikker HE,van den Ende CH

    更新日期:2012-05-01 00:00:00

  • Co-morbidity in psoriasis: mechanisms and implications for treatment.

    abstract:INTRODUCTION:Psoriasis is a common, chronic, immune-mediated inflammatory disorder. The disease is associated with several co-morbidities including cardiovascular disease, metabolic syndrome, and psychiatric disorders. It is important to identify and treat these co-morbidities because they have a strongly negative effe...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2016.1213631

    authors: Lønnberg AS,Skov L

    更新日期:2017-01-01 00:00:00

  • Immunological basis of stem cell therapy in liver diseases.

    abstract::Unbalanced immune cell populations or immune cell infiltration of the liver can disrupt the immune-privileged state of the liver, resulting in liver injury or fibrosis. Therefore, the treatment for liver diseases involves not only hepatic regeneration but also immunological regulation. Recent studies demonstrated that...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2014.930665

    authors: Cui L,Shi Y,Han Y,Fan D

    更新日期:2014-09-01 00:00:00

  • Harnessing immunotherapy for pediatric T-cell malignancies.

    abstract::Pediatric T-cell hematologic malignancies are a diverse group of rare cancers. The most common pediatric T-cell malignancies include T-cell acute lymphoblastic leukemia (T-ALL) and anaplastic large cell lymphoma (ALCL). Although the overall survival rates have improved markedly in recent years, children with relapsed ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1080/1744666X.2020.1732819

    authors: Diorio C,Teachey DT

    更新日期:2020-04-01 00:00:00

  • Clinical aspects of mucosal healing in inflammatory bowel diseases: what is it and what is the real value for the everyday practice?

    abstract::The course of inflammatory bowel diseases is heterogeneous and varies over time. Therefore, the search for predictive factors has increasingly become the focus of research. Mucosal healing has emerged as an important objective, as evidence indicates that it is associated with improved disease outcome. Nevertheless, ma...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2013.824675

    authors: Miheller P,Mandel MD,Mullner K,Lakatos PL

    更新日期:2013-09-01 00:00:00

  • The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond.

    abstract:INTRODUCTION:Secukinumab, an interleukin-17A (IL-17A) antagonist, is the first non-TNF alpha inhibitor agent licensed for ankylosing spondylitis (AS), which opens up a new era of alternative cytokine targets beyond TNF. Areas covered: This review explores the pathophysiology and scientific evidence behind the use of th...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2019.1561281

    authors: Dubash S,Bridgewood C,McGonagle D,Marzo-Ortega H

    更新日期:2019-02-01 00:00:00

  • CD40 ligand deficiency: treatment strategies and novel therapeutic perspectives.

    abstract:INTRODUCTION:CD40 ligand (CD40L) deficiency or X-linked Hyper-IgM syndrome is a severe primary immunodeficiency caused by mutations in the CD40L gene. Despite currently available treatments, CD40L-deficient patients remain susceptible to life-threatening infections and have poor long term survival. Areas covered: Here,...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2019.1573674

    authors: França TT,Barreiros LA,Al-Ramadi BK,Ochs HD,Cabral-Marques O,Condino-Neto A

    更新日期:2019-05-01 00:00:00

  • Analyzing the frequency and significance of the metabolic syndrome in patients with systemic lupus erythematosus.

    abstract::Evaluation of: Chung CP, Avalos I, Oeser A et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristic and cardiovascular risk factors. Ann. Rheum. Dis. 66(2), 208-214 (2007). Systemic lupus erythematosus is associated with higher rates of car...

    journal_title:Expert review of clinical immunology

    pub_type: 评论,杂志文章

    doi:10.1586/1744666X.3.2.121

    authors: Jara LJ,Medina G,Vega-Hinojosa O

    更新日期:2007-03-01 00:00:00

  • Chronotherapy with modified-release prednisone in patients with rheumatoid arthritis.

    abstract::Glucocorticoids are indispensable for the treatment of systemic inflammatory diseases such as rheumatoid arthritis (RA), though their beneficial effects have to be balanced with potential complications arising from high doses, prolonged use or dose splitting. A glucocorticoid formulation (modified-release prednisone) ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.11.95

    authors: Alten R

    更新日期:2012-02-01 00:00:00

  • Focus on the potential effects of treatments for spondylarthritides on cardiovascular risk.

    abstract::The past years have seen the publication of several studies on seronegative spondylarthritides (SpA) and cardiovascular risk as a result of new insights into the connection between inflammation and atherogenesis. Although the overall cardiovascular disease is a complex entity, chronic inflammation of SpA is known to c...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2014.875468

    authors: Ingegnoli F,Gualtierotti R,Artusi C,Lubrano E

    更新日期:2014-02-01 00:00:00

  • From mother to baby: antenatal exposure to monoclonal antibody biologics.

    abstract:INTRODUCTION:More women with autoimmune and inflammatory conditions are being treated with monoclonal antibody biologics (mAbs) during their pregnancy, to maintain clinical remission. The use of anti-tumor necrosis factor alpha agents in pregnancy appears to be safe but less is known regarding other mAbs, such as anti-...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2019.1561282

    authors: Pham-Huy A,Sadarangani M,Huang V,Ostensen M,Castillo E,Troster SM,Vaudry W,Nguyen GC,Top KA

    更新日期:2019-03-01 00:00:00

  • Adult and pediatric clinical trials of sublingual immunotherapy in the USA.

    abstract::Specific allergen immunotherapy has been practiced for allergic rhinoconjunctivitis for over 100 years and is the only treatment option that is disease modifying. In the USA, immunotherapy is usually administered via subcutaneous injection; this is the only route with a US FDA-approved formulation. There is growing in...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.12.41

    authors: Park D,Daher N,Blaiss MS

    更新日期:2012-08-01 00:00:00

  • Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus.

    abstract:INTRODUCTION:Despite the emergence of newer immunomodulating agents for systemic lupus erythematosus (SLE), a substantial proportion of patients still do not respond optimally. While the mechanisms for the differential responses to drug therapy are unclear, variation in drug exposure with the same dosing protocol relat...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2016.1212659

    authors: Mok CC

    更新日期:2017-01-01 00:00:00

  • Pathogens and immunologic memory in asthma: what have we learned?

    abstract::Animal models and clinical studies of asthma have generated important insights into the first effector phase leading to the development of allergic airway disease and bronchial hyper-reactivity. In contrast, mechanisms related to asthma chronicity or persistence are less well understood. The CD4(+) T-helper 2 lymphocy...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.1.4.589

    authors: Aronica MA,Vogel N

    更新日期:2005-11-01 00:00:00

  • Future clinical implications emerging from recent genome-wide expression studies in asthma.

    abstract::Host susceptibility to environmental triggers is the most likely explanation for the development of asthma. Quantifying gene expression levels in disease-relevant tissues and cell types using fast evolving genomic technologies have generated new hypotheses about the pathogenesis of asthma and identified new therapeuti...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2014.932249

    authors: Bérubé JC,Bossé Y

    更新日期:2014-08-01 00:00:00

  • A comparison of immunotherapy delivery methods for allergen immunotherapy.

    abstract:BACKGROUND:Allergic diseases are among the most common diseases in humans. Besides allergen avoidance, allergen-specific immunotherapy is the only causative treatment option. During recent years, many innovations of this therapy have emerged. METHODS:Selective literature research in Medline and PubMed, under the inclu...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1586/eci.13.25

    authors: Klimek L,Pfaar O

    更新日期:2013-05-01 00:00:00

  • Adalimumab for the treatment of psoriatic arthritis.

    abstract::Psoriatic arthritis (PsA) is a chronic inflammatory joint disease occurring in 6-39% of patients with psoriasis. Standard therapy of PsA includes nonsteroidal anti-inflammatory drugs, intra-articular steroids and disease-modifying antirheumatic drugs. Failure of standard therapy is an indication for anti-TNF-alpha the...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/eci.09.50

    authors: Poddubnyy DA,Rudwaleit M

    更新日期:2009-11-01 00:00:00

  • Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.

    abstract::Patients with systemic lupus erythematosus have a significantly increased risk of cardiovascular events due to atherosclerosis. Traditional cardiac risk factors cannot fully explain this increased risk. Recent evidence strongly suggests that atherosclerotic plaque is largely driven by inflammation and an active immuno...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.10.98

    authors: McMahon M,Hahn BH,Skaggs BJ

    更新日期:2011-03-01 00:00:00

  • What can we learn from systemic lupus erythematosus pathophysiology to improve current therapy?

    abstract::Systemic lupus erythematosus is an autoimmune disorder that can affect every organ system and cause a wide range of signs and symptoms. The precise pathogenic mechanism of disease remains uncertain, but it is clearly complex and involves the activation and deregulation of many components of the immune system. Certain ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2015.1078237

    authors: Vilas-Boas A,Bakshi J,Isenberg DA

    更新日期:2015-01-01 00:00:00

  • Treatment and monitoring of hypersensitivity pneumonitis.

    abstract:INTRODUCTION:Hypersensitivity pneumonitis (HP) is an immunologically induced lung disease that develops after inhalation of certain environmental antigens only in subjects with susceptibility to antigens. Therefore, both environmental and host immunological factors play important roles in the aetiology and pathogenesis...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2016.1182426

    authors: Miyazaki Y,Tsutsui T,Inase N

    更新日期:2016-09-01 00:00:00

  • Brodalumab for the treatment of psoriasis.

    abstract:INTRODUCTION:Psoriasis is a complex disease in which the alteration of the IL-23/Th17 axis appears to be crucial for its pathogenic mechanisms, and anti-IL17 agents are rapidly becoming important therapeutic tools. Brodalumab, a fully human Chinese hamster ovary cell-derived immunoglobulin G2 (IgG2) anti-IL-17RA monocl...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2016.1246957

    authors: Galluzzo M,D'adamio S,Bianchi L,Talamonti M

    更新日期:2016-12-01 00:00:00

  • Abatacept for the treatment of rheumatoid arthritis.

    abstract:INTRODUCTION:Rheumatoid arthritis (RA) is a complex disease in which different mechanisms are involved. Studies suggest a key role for aberrant pathways of T-cell activation in the initiation and perpetuation of disease. Abatacept is a fusion protein composed of the Fc region of the immunoglobulin G1 (IgG1) fused to th...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2019.1579642

    authors: Pombo-Suarez M,Gomez-Reino JJ

    更新日期:2019-04-01 00:00:00

  • Immunoregulatory gene polymorphisms and graft-versus-host disease.

    abstract::Graft-versus-host disease (GVHD) remains a significant complication that greatly enhances morbidity and mortality associated with hematopoietic stem cell transplantation. Key immunoregulatory molecules have been implicated in the pathogenesis of GVHD, but the mechanisms by which these molecules affect the incidence an...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/eci.09.44

    authors: Conway SE,Abdi R

    更新日期:2009-09-01 00:00:00

  • Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease.

    abstract::Inflammatory bowel diseases share common pathogenetic mechanisms that are not yet completely understood. It is clear, however, that the expression and production of cytokines in response to inflammation plays a key role in mediating the migration of activated leukocytes. The process of angiogenesis and the expression ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/eci.10.40

    authors: Fiorino G,Correale C,Fries W,Repici A,Malesci A,Danese S

    更新日期:2010-07-01 00:00:00

  • New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management.

    abstract:INTRODUCTION:Biologic drugs have revolutionized the treatment of moderate to severe psoriasis in recent years because of their high efficacy and low risk of toxicity. However, even within the group of biologic therapies, there are differences related to the different mechanisms of action. Areas covered: We review the m...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2018.1454835

    authors: Carrascosa JM,Del-Alcazar E

    更新日期:2018-04-01 00:00:00

  • The evolution of allergen and non-specific immunotherapy: past achievements, current applications and future outlook.

    abstract::Recent epidemiological studies estimated that more than 30% of European suffer from allergic rhinitis or conjunctivitis, while up to 20% suffer from asthma and 15% from allergic skin conditions, while for many other regions the prevalence is increasing. Allergen immunotherapy represents the only available treatment th...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2015.977260

    authors: Pajno GB,Nadeau KC,Passalacqua G,Caminiti L,Hobson B,Jay DC,Arasi S,Chiera F,Salzano G

    更新日期:2015-01-01 00:00:00